Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 37Melanoma 17Prostatic Neoplasms 16Lung Neoplasms 14Neoplasms 13Squamous Cell Carcinoma of Head and Neck 10Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 9Precancerous Conditions 8Lymphoma 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Leukemia 6Esophageal Neoplasms 6Colorectal Neoplasms 6Colonic Neoplasms 6Breast Neoplasms, Male 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Follicular 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Head and Neck Neoplasms 5Barrett Esophagus 5Adenocarcinoma Of Esophagus 5Salivary Gland Neoplasms 4Recurrence 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4

Interventions

selurampanel 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adrenocortical Adenoma × Biopsy × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡